United States

Merck & Co Inc (MRK)

MRK on New York Consolidated

28 Jul 2016
Change (% chg)

-- (--)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Merck plans to end partnership agreement with Alk Abello
Wednesday, 27 Jul 2016 01:25am EDT 

Alk Abello A/S : Said on Tuesday MSD (known as Merck in the United States and Canada) had informed ALK of its plans to end their partnership agreement . Said all rights to GRASTEK, RAGWITEK and investigational house dust mite SLIT-tablets for USA, Canada and Mexico to revert to ALK at no fee following six- month transition period . Ongoing registration processes for investigational HDM SLIT-tablet will continue . North America remains major business opportunity and ALK will now undertake full strategic analysis before deciding on revised strategy . Transaction has no impact on ALK's full-year outlook for 2016 .Acting CEO and Chairman Steen Riisgaard said: "The timing of this move is unexpected".  Full Article

Merck sets quarterly dividend of $0.46 per share
Tuesday, 26 Jul 2016 12:50pm EDT 

Merck & Co Inc :Sets quarterly dividend of $0.46 per share.  Full Article

Enigma biomedical announces research collaboration agreement with Biogen Inc and Merck
Monday, 25 Jul 2016 05:04pm EDT 

Enigma Biomedical Group Inc: Collaboration focused on qualification and validation of Tau imaging agent developed by Merck, MK-6240 .Announced a research collaboration agreement with Biogen Inc and Merck.  Full Article

Merck designated breakthrough therapy by FDA and gets prime status from EMA for ebola vaccine
Monday, 25 Jul 2016 08:00am EDT 

Merck & Co Inc : Merck is responsible for research, development, manufacturing, and regulatory efforts in support of v920 .Merck receives breakthrough therapy designation from fda and prime status from ema for investigational ebola zaire vaccine (v920).  Full Article

Merck provides regulatory update on Biologics application
Thursday, 21 Jul 2016 04:30pm EDT 

Merck & Co Inc : Fda has requested submission of new data and analyses from modify I and modify II clinical trials previously submitted . Merck provides regulatory update on Biologics licensing application for investigational agent Bezlotoxumab . Merck provides regulatory update on Biologics licensing application for investigational agent Bezlotoxumab .New Bezlotoxumab PDUFA date will be Oct. 23, 2016..  Full Article

Merck's Healthcare invests majority stake in Staywell
Monday, 11 Jul 2016 07:00am EDT 

Merck & Co Inc : Merck's Healthcare Services & Solutions invests in majority stake in Staywell .Terms of transaction were not disclosed..  Full Article

Merck Animal Health to buy controlling interest in Vallée S.A
Friday, 1 Jul 2016 12:05pm EDT 

Merck Animal Health: Will acquire approximately 93 pct of shares of Vallée S.A. at closing, in exchange for a payment of $400 mln .To acquire a controlling interest in Vallée S.A.  Full Article

Merck, Premier Inc collaborate to improve care for osteoporosis patients
Thursday, 30 Jun 2016 09:28am EDT 

Merck & Co In : Merck And Premier Inc collaborate to prevent fractures for osteoporosis patients .Financial terms of agreements were not disclosed.  Full Article

Merck's Keytruda shows superior progression-free, overall survival in lung cancer patients
Thursday, 16 Jun 2016 06:45am EDT 

Merck & Co Inc : Merck's keytruda® (pembrolizumab) demonstrates superior progression-free and overall survival compared to chemotherapy as first-line treatment in patients with advanced non-small cell lung cancer . Keynote-024 trial met its primary endpoint . Safety profile of keytruda in this trial was consistent with that observed in previously reported studies in patients with advanced nsclc . Based on these results, an independent data monitoring committee (dmc) has recommended that trial be stopped . Independent data monitoring committee recommended patients receiving chemotherapy in keynote-024 be offered opportunity to receive keytruda. .Keytruda was superior compared to chemotherapy for primary endpoint of progression-free survival, and secondary endpoint of overall survival.  Full Article

Merck to acquire Afferent Pharmaceuticals
Thursday, 9 Jun 2016 05:07pm EDT 

Merck & Co Inc : Merck to acquire Afferent Pharmaceuticals . Signed a definitive agreement under which Merck will acquire Afferent Pharmaceuticals . Under terms, Merck, through unit, to acquire outstanding stock of Afferent for an upfront payment of $500 million in cash .Afferent shareholders will be eligible to receive a total of up to an additional $750 million associated with attainment of certain milestones.  Full Article

U.S. probes contracts between Eli Lilly and PBMs

By Ankur Banerjee Eli Lilly and Co said it received a civil investigative demand from the U.S. attorney's office for the southern district of New York, requesting documents and information relating to contracts with pharmacy benefit managers (PBMs).